Tscan Therapeutics Inc (TCRX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Tscan Therapeutics Inc   (NASDAQ: TCRX)


Tscan Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Tscan Therapeutics Inc's ROI in the second quarter of 2026?
Tscan Therapeutics Inc recorded a cumulative net loss of $-118 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -59.82%.

Within the Healthcare sector 231 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3515 to 3659.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -29.68 % -18.22 % 7.24 % 24.91 % 36.64 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 140 189 217 240 274
Return On Investment (TTM) -59.82 % -54.04 % -49.98 % -52.06 % -48.88 %
TCRX's Overall Ranking # 3659 # 3515 # 2819 # 2744 # 2951
Seq. Investment Change TTM -14.46 % -11.4 % -5.22 % -2.11 % -0.51 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -118 -124 -130 -143 -137

TCRX Company Profile >> Back to TCRX Roi Comparisons >> See Annual TCRX Return On Investment



Return On Investment TCRX's Ranking
Within: No.
Industry # 25
Sector # 232
Overall # 3659

Return On Investment Statistics
High Average Low
-10.63 %
-37.31 %
-49.73 %
(Mar 31 2022)   (Jun 30 2026)



  News about Tscan Therapeutics Inc Return on Investment ROI

TScan Therapeutics Raises $150 Million in Upsized Public Offering to Accelerate Breakthrough Cancer Therapies

April 17, 2024

TScan Therapeutics Raises $150 Million in Upsized Public Offering to Advance Cancer Therapies
TScan Therapeutics, a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR)-engineered T cell therapies (TCR-T) for cancer treatment, recently announced the pricing of an underwritten public offering. The company is offering 2,472,581 shares of its voting common stock at a public offering price of $7.1300 per share. Additionally, pre-funded warrants to purchase up to 18,577,419 shares of voting common stock are being sold at $7.1299 per warrant. TScan has also granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of voting common stock at the public offering price.
With the pricing of this public offering, TScan expects to raise approximately $150.1 million in gross proceeds. This amount does not include underwriting discounts, commissions, and other estimated offering expenses. The offering is anticipated to close on or around April 19, 2024, subject to customary closing conditions.





Financial Statements
Tscan Therapeutics Inc's II. Quarter Investments $ 140 Millions TCRX's Balance sheet
Tscan Therapeutics Inc's II. Quarter Income $ -30 Millions Quarterly TCRX's Income Statement
TCRX's Income by Division See TCRX's Income by Division


TCRX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 156 274 183 129 162
Y / Y Investment Growth -43.28 % 49.8 % 42.26 % -20.69 % -
Net Income in Millions -130 -127 -89 -66 -49
Y / Y Net Income Growth - - - - -
Annual Return On Investment -83.37 % -46.46 % -48.7 % -51.42 % -29.95 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TCRX's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TCRX's Competitors
Subscribers only: Roi for Tscan Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for TCRX's Customers

Other Ratios
TCRX's Roa TCRX's Inventory Turnover Ratio TCRX's Growth Rates TCRX's Dividend Statistics
TCRX's Profitability Ratios TCRX's Asset Turnover Ratio TCRX's Dividend Growth
TCRX's Roe TCRX's Valuation Ratios TCRX's Financial Strength Ratios TCRX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-12T06:25:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.